Abstract:Study question: Do high-risk patients who develop severe early ovarian hyperstimulation syndrome (OHSS) and receive low-dose GnRH antagonist in the luteal phase have lower live birth rates compared with high-risk patients who do not develop severe early OHSS and do not receive GnRH antagonist in the luteal phase? Summary answer: Low-dose luteal GnRH antagonist administration in women with severe early OHSS is associated with similar live birth rates to that of high-risk patients who do not develop severe early OHSS and do not receive GnRH antagonist in the luteal phase. What is known already: It has been reported that luteal GnRH antagonist administration in patients with established severe early OHSS appears to prevent patient hospitalization and results in quick regression of the syndrome on an outpatient basis. However, the effect of such treatment on pregnancy outcome has been investigated in only a small number of animal studies. Study design, size, duration: This is a prospective cohort study of 192 IVF patients who were at high risk for OHSS and who did not wish to cancel embryo transfer and have all embryos cryopreserved. The study was conducted between January 2009 and December 2011 at Eugonia Assisted Reproduction Unit. Participants/materials, setting, methods: Patients were <40 years of age, with polycystic ovaries, at high risk for OHSS (defined by the presence of at least 20 follicles ≥11 mm on the day of triggering of final oocyte maturation) and not willing to cancel embryo transfer and cryopreserve all embryos, if severe early OHSS was diagnosed by Day 5 of embryo culture. Patients who were diagnosed with severe early OHSS on Day 5 post-oocyte retrieval were administered 0.25 mg of ganirelix for 3 days, from Day 5 until and including Day 7 (OHSS + antag group, n = 22). High-risk patients who did not develop the severe early OHSS did not receive GnRH antagonist in the luteal phase (control group, n = 172). All patients underwent embryo transfer on Day 5. Main results and the role of chance: Live birth rates (40.9 versus 43.6%), ongoing pregnancy rates (45.5 versus 48.8%), clinical pregnancy rates (50 versus 65.1%), positive hCG (72.7 versus 75%), duration of gestation (36.86 ± 0.90 weeks versus 36.88 ± 2.38 weeks) and neonatal weight (2392.73 ± 427.04 versus 2646.56 ± 655.74 g) were all similar in the OHSS + antag and control groups, respectively. The incidence of major congenital malformations was 2.9% (3/103) in children born in the control group compared with no cases (0/14) in children born following luteal GnRH antagonist administration. No stillbirths or intrauterine deaths, and no cases of pregnancy-induced late OHSS were recorded in either group. None of the 22 patients with severe early OHSS required hospitalization following luteal antagonist administration. Ovarian volume, ascites, hematocrit, white blood cell count, serum estradiol and progesterone decreased significantly (P < 0.001) by the end of the monitoring period (Day 11 post-oocyte retrieval), indicating rapid resolution of the severe OHSS. Limitations, reasons for caution: This is a prospective cohort investigation with a very limited number of patients receiving the intervention and a larger number of control patients. Our findings suggest that low-dose luteal GnRH antagonist administration during the peri-implantation period may be safe, although larger studies with follow-up of the children born are required. Wider implications of the findings: Our study suggests for the first time that low-dose luteal GnRH antagonist administration in women with severe early OHSS is associated with a favourable IVF outcome, comparable to control high-risk patients without severe OHSS and not receiving the intervention. Regarding the wider implications on the concept of an OHSS-free clinic, administration of GnRH antagonist in the luteal phase may present a tertiary management level in patients with established severe OHSS, along with the use of GnRH antagonist protocols for primary prevention and the replacement of hCG with GnRH agonist for triggering final oocyte maturation for secondary prevention. However, at present, fresh embryo transfer combined with antagonist administration should only be used with caution by experienced practitioners, after carefully deciding which patients can have a fresh transfer or embryo cryopreservation, until the current data are confirmed by larger trials.

Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Research on the Protocol of Limited Ovarian Stimulation to Prevent Ovarian Hyperstimulation Syndrome

The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium.

Effects of Gonadotropin-Releasing Hormone Antagonists on the Expression of Vascular Endothelial Growth Factor and Its Receptors in a Rat Model of Ovarian Hyperstimulation Syndrome.

Comparison the Effectiveness and Safety of Letrozolestimulated and Hormone Replacement Treatment in Endometrial Preparation for Frozen Embryo Transfer in Patients with Polycystic Ovary Syndrome

Letrozole Stimulation in Endometrial Preparation for Cryopreserved–thawed Embryo Transfer in Women with Polycystic Ovarian Syndrome: A Pilot Study

Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS

The effect of oral contraceptive pill and luteal phase estradiol pretreatment on the patients with poor ovarian response

Elevated Follicular Cortisone Level is a Negative Predictor of Clinical Pregnancy in Women Undergoing Fresh Embryo Transfer

Obstetric Outcome Analyses of 132 Cycles in Vitro Fertilized Pregnancies Complicated by Moderate and Severe Ovarian Hyperstimulation Syndrome

Clinical Analyses for 93 Cycles of Moderate and Severe Ovarian Hyperstimulation Syndrome

Serum Steroid Metabolome on the Day of Oocyte Retrieval in Women with Polycystic Ovarian Syndrome and Its Association with Pregnancy Outcome of in Vitro Fertilization.

Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol

Pregnancy Outcome in Late-Onset Severe OHSS Patients Following Different Ascetic Fluid Drainage and Comparison with the Non-Ohss IVF Patients

Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial

Effect of transdermal estrogen for luteal support in ovarian hypersensitivity patients undergoing IVF

Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS

The Effect of Luteinising Hormone Suppression in In Vitro Fertilisation Antagonist Cycles

Influence of Different Types of Ovarian Hyperstimulation Syndrome on Obstetric Outcome

Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation

Investigation on the Risk Factors for Late-Onset OHSS: a Retrospective Case–control Study